Please call the office for information about accepted insurance plans.
462 First Avenue, OBV-C&D Building
5th Floor, 556
New York, NY 10016
EMBER-4: A Randomized Open-Label Phase 3 Study of Adjuvant Imlunestrant vs Standard Adjuvant Endocrine Therapy in Patients who have Previously Received 2 to 5 years of Adjuvant Endocrine Therapy for ER+ HER2- Early Breast Cancer with an Increased Risk of Recurrence.
Journal of Clinical Oncology. 2023; 41(16_suppl):
Stem cells. 2009 Dec ; 27(12):2884-95
Nature cell biology. 2009 Dec ; 11(12):1451-7